The FDA has released draft guidance outlining when six-month toxicity studies in non-human primates may be reduced or eliminated for certain monoclonal antibody programs. The update shifts how the agency evaluates nonclinical safety packages for biologics, placing greater emphasis on human-relevant data rather than default long-duration primate studies. The FDA noted that monoclonal antibody programs […]